Oppenheimer Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price Target of $48
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on Dianthus Therapeutics with an Outperform rating and set a price target of $48.
October 03, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Dianthus Therapeutics with an Outperform rating and a price target of $48, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $48 by a reputable analyst like Oppenheimer is likely to positively influence investor sentiment and could lead to an increase in DNTH's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100